Overview
Sable Bio, a London-based AI startup focused on drug safety, has raised $3.75 million in seed funding to enhance its platform that helps pharmaceutical companies identify safety risks earlier in drug discovery. The funding round was led by MMC Ventures, with participation from existing investors Episode 1 Ventures and Seedcamp.
Products
Loading...
Recent Deals
Investors: MMC Ventures, Episode 1 Ventures, Seedcamp
Sable Bio, a London-based AI startup focused on drug safety, has raised $3.75 million in seed funding to enhance its platform that helps pharmaceutical companies identify safety risks earlier in drug discovery. The funding round was led by MMC Ventures, with participation from existing investors Episode 1 Ventures and Seedcamp.
Investors: MMC Ventures, Episode 1 Ventures, Seedcamp
London-based drug safety startup Sable Bio has secured $3.75 million in seed funding led by MMC Ventures, with support from Episode 1 Ventures and Seedcamp. The funding aims to enhance its platform that helps pharmaceutical companies detect safety risks earlier in drug development, addressing the costly issue of unexpected toxicity in clinical trials. Sable has generated $0.5 million in revenue and signed agreements with top pharma firms, showcasing the demand for its innovative safety assessment solutions.